Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
Clinical trial NCT04997798 · UNKNOWN
Trial details
- NCT number
- NCT04997798
- Sponsor
- First Affiliated Hospital of Zhejiang University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-01
- Primary completion
- 2024-12-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.